A dual angiotensin II receptor antagonist and neprilysin inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

LCZ696

Item No. 23425

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-(1-oxopentyl)-N-[[2’-(2H-tetrazol-5-yl)[1,1’-biphenyl]-4-yl]methyl]-L-valine compd. with α-ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl[1,1’-biphenyl]-4-pentanoate, sodium salt, hydrate (2:2:6:5)
CAS Number
936623-90-4
Molecular Formula
C24H29N5O3 • C24H29NO5 • 5/2H2O • 3Na
Formula Weight
916.0
Purity
≥98% (1:1 ratio of Valsartan and AHU377)
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 20 mg/mlEthanol: 30 mg/mlPBS (pH 7.2): 10 mg/ml
λmax
251 nm
SMILES
O=C(CCCC)N([C@H](C(O)=O)C(C)C)CC1=CC=C(C2=CC=CC=C2C3=NNN=N3)C=C1.C[C@@H](C(OCC)=O)C[C@H](NC(CCC(O)=O)=O)CC(C=C4)=CC=C4C5=CC=CC=C5.O.O.O.[Na].[Na].[Na]
InChi Code
InChI=1S/C24H29N5O3.C24H29NO5.3Na.9H2O/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;;;;;;;;;/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28);4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;9*1H2/t22-;17-,21+;;;;;;;;;;;;/m01............/s1
InChi Key
YYXACTPPFJVFTL-DKPGDUSBSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $41

    Add

    25 mg

    $80

    Add

    50 mg

    $128

    Add
    Product Description

    LCZ696 is a dual angiotensin II receptor antagonist and neprilysin inhibitor that is a combination of the nonpeptide angiotensin II receptor antagonist valsartan (Item No. 14178) and AHU377 (Item No. 21473), a prodrug of LBQ657 (Item No. 19829), which is an inhibitor of the zinc metallopeptidase neprilysin.1,2,3 LCZ696 (2-60 mg/kg) induces a dose-dependent decrease in mean arterial pressure in rats expressing human renin and angiotensinogen, a double-transgenic model for angiotensin II-dependent hypertension.3 Formulations containing LCZ696 have been used in the treatment of chronic heart failure.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Burnier, M. Angiotensin II type 1 receptor blockers. Circulation 103(6), 904-912 (2001).

    2. Schiering, N., D'Arcy, A., Villard, F., et al. Structure of neprilysin in complex with the active metabolite of sacubitril. Sci. Rep. 6, 27909 (2016).

    3. Gu, J., Noe, A., Chandra, P., et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J. Clin. Pharmacol. 50(4), 401-414 (2010).